Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Market Cap	48.00B
Revenue (ttm)	11.21B
Net Income (ttm)	558.54M
Shares Out	300.00M
EPS (ttm)	1.86
PE Ratio	85.94
Forward PE	n/a
Dividend	1.11 (0.73%)
Ex-Dividend Date	Oct 8, 2024

Volume	239,370
Average Volume	1,069,009
Open	150.90
Previous Close	148.60
Day's Range	146.80 - 151.60
52-Week Range	54.20 - 152.50
Beta	1.09
RSI	81.24
Earnings Date	Mar 3, 2025

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 622
• Stock Exchange: Istanbul Stock Exchange
• Ticker Symbol: GENIL

Financial Performance

In 2023, IST:GENIL's revenue was 8.15 billion, a decrease of -23.38% compared to the previous year's 10.64 billion. Earnings were 454.58 million, a decrease of -28.97%.